Eosinophilic Granuloma (Histiocytosis X) Follow-up

  • Author: Eleanor M Summerhill, MD, FACP, FCCP; Chief Editor: Zab Mosenifar, MD   more...
 
Updated: Jan 17, 2012
 

Further Inpatient Care

  • Inpatient admission is indicated in pulmonary Langerhans cell histiocytosis X (PLCH) patients only to manage complications related to the disease as listed below.
  • Patients with superimposed respiratory infections, such as pneumonia, may require inpatient treatment.
  • Patients with spontaneous pneumothorax may require chest-tube placement and subsequent in-patient care. The recurrence rate of secondary spontaneous pneumothorax in PLCH is high. Therefore, some experts recommend surgical intervention, such as mechanical pleurodesis, parietal pleurectomy, or talc insufflation, to prevent further occurrences after the initial episode.
  • Acute respiratory failure necessitating in-patient management may occur as the result of a superimposed respiratory infection or spontaneous pneumothorax. Respiratory failure may also occur as a manifestation of end-stage disease.
Next

Further Outpatient Care

  • In the care of patients with pulmonary Langerhans cell histiocytosis X (PLCH) , important considerations include the patients' smoking history and current smoking status, the presence or absence of extrapulmonary disease and constitutional symptoms, and close monitoring for progression of pulmonary disease.
  • Pulmonary artery hypertension is a known complication of infiltrative lung diseases, and in PLCH the magnitude of pulmonary artery hypertension may be greater than expected for given the degree of hypoxemia or level of impairment on pulmonary function testing.
  • The increased risk of pulmonary malignancies must be considered.
  • Smoking cessation counseling and adjunctive pharmacologic therapy with bupropion and nicotine replacement are key components of long-term management.
  • Perform pulmonary function testing and radiographic studies every 3-6 months, as the patient's clinical condition warrants.
  • Assess arterial oxygen saturation both at rest and with activity.
  • Echocardiography should be considered in all patients with clinically significant dyspnea in order to screen for pulmonary artery hypertension.
    • If echocardiographic results suggest moderate-to-severe pulmonary artery hypertension, these findings should be further evaluated and confirmed with right-heart catheterization.
    • At the time of catheterization, the response to vasodilators may also be assessed.
  • Patients should be vaccinated annually for influenza and should also receive the pneumococcal vaccine.
Previous
Next

Inpatient & Outpatient Medications

  • As previously discussed, corticosteroid therapy may be considered in some patients with pulmonary Langerhans cell histiocytosis X (PLCH).
  • Patients with an obstructive ventilatory defect on pulmonary function testing may benefit from bronchodilator therapy.
  • Supplemental oxygen therapy is indicated for all patients with either resting or exertional hypoxemia. Oxygen therapy may help to prevent or slow progression of pulmonary hypertension and cor pulmonale, and it provides a mortality benefit in chronic obstructive pulmonary disease.
Previous
Next

Deterrence/Prevention

  • Effective antismoking measures can prevent pulmonary Langerhans cell histiocytosis X (PLCH). See Medscape's Smoking Resource Center.
Previous
Next

Complications

  • Spontaneous pneumothorax is a common complication (10-20%) in pulmonary Langerhans cell histiocytosis X (PLCH).
  • PLCH is associated with an increased risk of malignancy, including Hodgkin and non-Hodgkin lymphoma, myeloproliferative disorders, and bronchogenic carcinoma.[11]
  • Pathologic fracture may occur at the site of bone lesions.
  • Diabetes insipidus occurs in 10-15% of patients and indicates disease in the central nervous system.
  • Pulmonary artery hypertension and cor pulmonale may develop as a result of hypoxemia and/or vascular disruption due to PLCH lesions.
Previous
Next

Prognosis

  • The prognosis for pulmonary Langerhans cell histiocytosis X (PLCH) varies and is related to smoking cessation. Most patients who continue to smoke experience disease progression, but for those who successfully quit smoking, the disease often stabilizes or regresses.
  • Retrospective studies suggest that the following factors are associated with adverse outcomes in PLCH:
    • Extremes of age
    • Extensive cysts and honeycombing radiographically
    • Prolonged corticosteroid therapy
    • Multiorgan involvement
    • Abnormal pulmonary function, including reduced gas exchange, as measured by diffusing capacity for carbon monoxide; obstructive ventilatory defect (reduced ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity [FVC], or FEV1/FVC); and/or evidence of airtrapping (high residual volume/total lung capacity)
  • Young men who have diabetes insipidus have the worst prognosis.
  • Favorable signs include the radiographic finding of sparing of the costophrenic angles and a cellular, nonfibrotic biopsy specimen.
Previous
Next

Patient Education

  • The public must be educated about the likely etiologic role of cigarette smoking. Pulmonary Langerhans cell histiocytosis X (PLCH)is thought to be largely preventable through smoking cessation.
  • Instruct patients to promptly report the development of hemoptysis. This symptom may indicate malignancy or superimposed bacterial/fungal infection, such as Aspergillus species infection.
Previous
 
Contributor Information and Disclosures
Author

Eleanor M Summerhill, MD, FACP, FCCP  Associate Professor of Medicine, Division of Pulmonary and Critical Care Medicine, Warren Alpert Medical School of Brown University; Director, Internal Medicine Residency Program, Memorial Hospital of Rhode Island

Eleanor M Summerhill, MD, FACP, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Thoracic Society, Association of Program Directors in Internal Medicine, and Rhode Island Medical Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Michael Peterson, MD  Chief of Medicine, Vice-Chair of Medicine, University of California, San Francisco, School of Medicine; Endowed Professor of Medicine, University of California, San Francisco-Fresno, School of Medicine

Michael Peterson, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and American Thoracic Society

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Daniel R Ouellette, MD, FCCP  Associate Professor of Medicine, Wayne State University School of Medicine; Consulting Staff, Pulmonary Disease and Critical Care Medicine Service, Henry Ford Health System

Daniel R Ouellette, MD, FCCP is a member of the following medical societies: American College of Chest Physicians and American Thoracic Society

Disclosure: Nothing to disclose.

Timothy D Rice, MD  Associate Professor, Departments of Internal Medicine and Pediatrics and Adolescent Medicine, St Louis University School of Medicine

Timothy D Rice, MD is a member of the following medical societies: American Academy of Pediatrics and American College of Physicians

Disclosure: Nothing to disclose.

Chief Editor

Zab Mosenifar, MD  Director, Division of Pulmonary and Critical Care Medicine, Director, Women's Guild Pulmonary Disease Institute, Professor and Executive Vice Chair, Department of Medicine, Cedars Sinai Medical Center, University of California, Los Angeles, David Geffen School of Medicine

Zab Mosenifar, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Federation for Medical Research, and American Thoracic Society

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of eMedicine gratefully acknowledge the contributions of previous author, Robert S. Crausman, MD, MMS, to the development and writing of this article.

References

  1. Podbielski FJ, Worley TA, Korn JM, Connolly MM. Eosinophilic granuloma of the lung and rib. Asian Cardiovasc Thorac Ann. Apr 2009;17(2):194-5. [Medline].

  2. Gaensler EA, Carrington CB. Open biopsy for chronic diffuse infiltrative lung disease: clinical, roentgenographic, and physiological correlations in 502 patients. Ann Thorac Surg. Nov 1980;30(5):411-26. [Medline].

  3. Colby TV, Lombard C. Histiocytosis X in the lung. Hum Pathol. Oct 1983;14(10):847-56. [Medline].

  4. Thomeer M, Demedts M, Vandeurzen K. Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin Belg. May-Jun 2001;56(3):163-72. [Medline].

  5. Watanabe R, Tatsumi K, Hashimoto S, Tamakoshi A, Kuriyama T. Clinico-epidemiological features of pulmonary histiocytosis X. Intern Med. Oct 2001;40(10):998-1003. [Medline].

  6. Vassallo R, Ryu JH, Schroeder DR, Decker PA, Limper AH. Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N Engl J Med. Feb 14 2002;346(7):484-90. [Medline].

  7. Delobbe A, Durieu J, Duhamel A, Wallaert B. Determinants of survival in pulmonary Langerhans' cell granulomatosis (histiocytosis X). Groupe d'Etude en Pathologie Interstitielle de la Société de Pathologie Thoracique du Nord. Eur Respir J. Oct 1996;9(10):2002-6. [Medline].

  8. [Guideline] Prakash UB. Uncommon causes of cough: ACCP evidence-based clinical practice guidelines. Chest. Jan 2006;129(1 Suppl):206S-219S. [Medline].

  9. Stacher E, Beham-Schmid C, Terpe HJ, Simiantonaki N, Popper HH. Pulmonary histiocytic sarcoma mimicking pulmonary Langerhans cell histiocytosis in a young adult presenting with spontaneous pneumothorax: a potential diagnostic pitfall. Virchows Arch. Aug 2009;455(2):187-90. [Medline].

  10. Alalawi R, Whelan T, Bajwa RS, Hodges TN. Lung transplantation and interstitial lung disease. Curr Opin Pulm Med. Sep 2005;11(5):461-6. [Medline].

  11. Misaki H, Yamauchi T, Arai H, et al. Secondary malignant fibrous histiocytoma following refractory langerhans cell histiocytosis. J Clin Exp Hematop. May 2009;49(1):33-7. [Medline].

  12. Arico M. Langerhans cell histiocytosis in adults: more questions than answers?. Eur J Cancer. Jul 2004;40(10):1467-73. [Medline].

  13. Chaowalit N, Pellikka PA, Decker PA, et al. Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis. Mayo Clin Proc. Oct 2004;79(10):1269-75. [Medline].

  14. Crausman RS, Jennings CA, Tuder RM, Ackerson LM, Irvin CG, King TE Jr. Pulmonary histiocytosis X: pulmonary function and exercise pathophysiology. Am J Respir Crit Care Med. Jan 1996;153(1):426-35. [Medline].

  15. Dacic S, Trusky C, Bakker A, Finkelstein SD, Yousem SA. Genotypic analysis of pulmonary Langerhans cell histiocytosis. Hum Pathol. Dec 2003;34(12):1345-9. [Medline].

  16. King TE, Crausman RS. Pulmonary histiocytosis X. In: Fishman AP, ed. Fishman's Pulmonary Diseases and Disorders. Vol 1. 3rd ed. New York, NY: Mc-Graw Hill; 1998:1163-70.

  17. Sundar KM, Gosselin MV, Chung HL, Cahill BC. Pulmonary Langerhans cell histiocytosis: emerging concepts in pathobiology, radiology, and clinical evolution of disease. Chest. May 2003;123(5):1673-83. [Medline].

  18. Tazi A. Adult pulmonary Langerhans' cell histiocytosis. Eur Respir J. Jun 2006;27(6):1272-85. [Medline].

  19. Vassallo R, Ryu JH. Pulmonary Langerhans' cell histiocytosis. Clin Chest Med. Sep 2004;25(3):561-71, vii. [Medline].

 
Previous
Next
 
Low-power photomicrograph of a lung-tissue specimen that demonstrates the classic stellate nodule of pulmonary histiocytosis X (hematoxylin-eosin stain).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.